Trial · NCT00145704
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
NCT00145704, Not applicable, Terminated, State University of New York - Upstate Medical University; results first posted 2013-04-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density. Trials, record NCT00145704. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00145704
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
- NCT number
- NCT00145704
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 6 participants, actual
- Lead sponsor
- State University of New York - Upstate Medical University
- Conditions
- Osteopenia
- Interventions
- bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
- First posted
- 2005-09-05
- Last updated
- 2013-04-08
- Results first posted
- 2013-04-08
- Limitations and caveats
- Early termination due to low enrollment, and lost to follow up of three subjects. Data was limited and therefore not reviewed/analyzed
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Total Body Bone Mineral Density During an 18 Month Period | 18 months | For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Total Body Bone Mineral Density During an 18 Month Period | 18 months | Data analyis halted, due to low enrollment,no outcomes to report |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bisphosphonate and Growth Hormone | 3 | |
| Overall Study | STARTED | Growth Hormone Only | 3 | |
| Overall Study | COMPLETED | Bisphosphonate and Growth Hormone | 0 | |
| Overall Study | COMPLETED | Growth Hormone Only | 0 | |
| Overall Study | NOT COMPLETED | Bisphosphonate and Growth Hormone | 3 | |
| Overall Study | NOT COMPLETED | Growth Hormone Only | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bisphosphonate and Growth Hormone Use | ||
| Total, all-cause mortality | Growth Hormone Only | ||
| Total, other adverse events | Bisphosphonate and Growth Hormone Use | 0 | 3 |
| Total, other adverse events | Growth Hormone Only | 0 | 3 |
| Total, serious adverse events | Bisphosphonate and Growth Hormone Use | 0 | 3 |
| Total, serious adverse events | Growth Hormone Only | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Bisphosphonate and Growth Hormone Use vs Growth Hormone Only: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00145704
GET https://conductscience.org/api/trials/v1/NCT00145704/registered